Počet záznamů: 1  

The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?

  1. 1.
    SYSNO ASEP0369486
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevThe Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?
    Tvůrce(i) Zobalová, Renata (BTO-N) RID
    Prokopová, Kateřina (BTO-N) ORCID
    Stantic, M. (US)
    Stapelberg, M. (US)
    Dong, L.-F. (US)
    Ralph, S.J. (US)
    Akporiaye, E. (US)
    Neužil, Jiří (BTO-N) RID
    Zdroj.dok.Antioxidants & Redox Signaling. - : Mary Ann Liebert - ISSN 1523-0864
    Roč. 15, č. 12 (2011), s. 2989-3002
    Poč.str.13
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaCancer stem-like cells ; protein CD133 ; apoptosis
    Vědní obor RIVEB - Genetika a molekulární biologie
    CEPGA204/08/0811 GA ČR - Grantová agentura ČR
    GA305/07/1008 GA ČR - Grantová agentura ČR
    CEZAV0Z50520701 - BTO-N (2007-2013)
    UT WOS000296588900006
    DOI10.1089/ars.2010.3785
    AnotaceRecent research has shown that tumors contain a small subpopulation of stem-like cells that are more resistant to therapy and that are likely to produce second-line tumors. Cancer stem-like cells (CSCs) have been characterized by a variety of markers, including the plasma membrane protein CD133, which is also indicative of the increase of stemness of cultured cancer cells growing as spheres. While the function of this protein has not yet been clearly defined, it may have a role in the stem-like phenotype of CSCs that cause (re-)initiation of tumors as well as their propagation. We hypothesize that CD133 selects for CSC survival against not only immunosurveillance mechanisms but also stress-induced apoptosis. High level of expression of CD133 may be a useful marker of more aggressive tumors that are recalcitrant toward established therapies. Compelling preliminary data indicate that drugs targeting mitochondria may be utilized as a novel, efficient cancer therapeutic modality.
    PracovištěBiotechnologický ústav
    KontaktMonika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700
    Rok sběru2012
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.